Naegoti (Fingolimod)

Fingolimod, the active ingredient in Naegoti, is a sphingosine‑1‑phosphate receptor modulator presented as an oral formulation for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients. GNH USA supplies Naegoti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naegoti (fingolimod) acts on the sphingosine‑1‑phosphate pathway to modify disease activity in multiple sclerosis. - Relapsing‑Remitting Multiple Sclerosis: reduces the frequency of clinical relapses and slows MRI lesion accumulation. - Secondary Progressive Multiple Sclerosis with active disease: delays disability progression and lowers relapse risk. - Clinically Isolated Syndrome at high risk of conversion: postpones the onset of definitive multiple sclerosis.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nausea: occasional, may improve with food. - Diarrhea: usually self‑limiting. - Fatigue: persistent tiredness reported by some patients. - Upper respiratory tract infection: mild cold‑like symptoms. - Elevated liver enzymes: mild transaminase rise detected in routine labs.

Serious or Rare Side Effects: - Severe infections: opportunistic or serious bacterial infections. - Cardiac arrhythmia: bradycardia or heart block, especially after first dose. - Macular edema: visual disturbances requiring ophthalmologic evaluation. - Significant liver injury: marked transaminase elevation or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Respiratory complications: severe asthma or bronchospasm.

Before initiating therapy, clinicians should assess baseline status and monitor for specific risks. - Liver monitoring: perform baseline and periodic liver function tests during treatment. - Cardiac evaluation: obtain ECG and monitor heart rate after the first dose, especially in patients with cardiac history. - Infection screening: evaluate for active infections and vaccinate appropriately before starting. - Pregnancy counseling: discuss potential fetal risks and advise effective contraception. - Live vaccine avoidance: do not administer live attenuated vaccines while on therapy. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Fingolimod may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase fingolimod exposure. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Drugs that prolong QT interval (e.g., certain antiarrhythmics): may exacerbate cardiac effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antihypertensive agents: potential additive blood pressure effects. - Antiplatelet or anticoagulant drugs: increased bleeding risk. - Non‑live vaccines: monitor immune response, may be attenuated.